How has been the historical performance of the Solara Active PP?

No Data Available for this Stock

how big is Solara Active PP?

As of June 06, Solara Active Pharma Sciences Ltd Partly Paidup has a market capitalization of 389.00 Cr, categorizing it as a Micro Cap. There is no available financial data for the latest four quarters or balance sheet information.

Market Cap: As of June 06, Solara Active Pharma Sciences Ltd Partly Paidup has a market capitalization of 389.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: As of June 06, there is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: As of June 06, there is no valid Consolidated or Standalone balance sheet data available, including values for Shareholder's Funds and Total Assets for the latest annual period.

When is the next results date for Solara Active PP?

No Upcoming Board Meetings

Has Solara Active PP declared dividend?

No Dividend History Available

What is the technical trend for Solara Active PP?

As of June 4, 2025, Solara Active PP shows a neutral trend with a slight bullish inclination due to a mildly bullish weekly MACD and RSI, despite daily moving averages being mildly bearish and no clear trend from Dow Theory and OBV.

As of 4 June 2025, the technical trend for Solara Active PP has changed from mildly bearish to sideways. The weekly MACD is mildly bullish, and the RSI is bullish, indicating some positive momentum in the short term. However, daily moving averages are mildly bearish, suggesting caution. The Bollinger Bands on the weekly chart are also bullish, supporting the upward potential. Dow Theory and OBV show no clear trend in both weekly and monthly time frames, indicating a lack of strong directional movement. Overall, the current stance is neutral with a slight bullish inclination, driven primarily by the weekly MACD and RSI.

Who are the peers of the Solara Active PP?

Peers of Solara Active PP include Venus Remedies, Ind-Swift Labs, Jenburkt Pharma, Zim Laboratories, Albert David, Medicamen Biotec, Valiant Laborato, Brooks Lab, Nectar Lifesci, and Infinium Pharma. Jenburkt Pharma has the highest 1-year return at 47.73%, while Solara Active PP leads with 59.14%.

Peers: The peers of Solara Active PP are Venus Remedies, Ind-Swift Labs., Jenburkt Pharma, Zim Laboratories, Albert David, Medicamen Biotec, Valiant Laborato, Brooks Lab., Nectar Lifesci., and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Infinium Pharma, while Average management risk is found at Venus Remedies, Jenburkt Pharma, Zim Laboratories, Albert David, Medicamen Biotec, and the rest. Below Average management risk is present at Ind-Swift Labs., Valiant Laborato, Brooks Lab., and Nectar Lifesci. Growth is rated as Excellent for Venus Remedies, Jenburkt Pharma, Albert David, Medicamen Biotec, and the rest show Below Average growth, including Ind-Swift Labs., Zim Laboratories, and Valiant Laborato. Infinium Pharma stands out with Good growth. Capital Structure is Excellent for Venus Remedies, Jenburkt Pharma, Albert David, Medicamen Biotec, and the rest, while Average is noted for Zim Laboratories, and Below Average for Ind-Swift Labs., Valiant Laborato, Brooks Lab., and Nectar Lifesci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jenburkt Pharma at 47.73%, while Ind-Swift Labs. has the lowest at -26.31%. Solara Active PP's 1-year return of 59.14% is higher than both of these peers. Additionally, several peers, including Ind-Swift Labs., Albert David, Medicamen Biotec, Valiant Laborato, Brooks Lab., Nectar Lifesci., and Infinium Pharma, have negative six-month returns.

What does Solara Active PP do?

Solara Active Pharma Sciences Ltd Partly Paidup is a micro-cap company in the Pharmaceuticals & Biotechnology sector with no reported sales or profits. It has a market cap of INR 541 Cr and key metrics such as a P/E ratio and dividend yield of 0.00%.

Overview: <BR>Solara Active Pharma Sciences Ltd Partly Paidup operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not provided. There are no reported sales or profit figures for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 541 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price-to-Book: 0.00<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

Which are the latest news on Solara Active PP?

Why is Solara Active PP falling/rising?

As of 04-Dec, the stock price of Solara Active Pharma Sciences Ltd Partly Paidup is currently at 381.70, reflecting a decline of 0.82%. The stock has significantly underperformed over various time frames, contrasting with positive returns from the benchmark Sensex, indicating ongoing challenges for the company.

As of 04-Dec, the stock price of Solara Active Pharma Sciences Ltd Partly Paidup is falling, currently at 381.70, which reflects a decrease of 3.15 (-0.82%). This decline is part of a broader trend, as the stock has underperformed significantly over various time frames, including a 1-month drop of 11.83% and a year-to-date decrease of 6.70%. In contrast, the benchmark Sensex has shown positive returns during these periods, with a 1-month gain of 1.70% and a year-to-date increase of 10.10%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 1.11%. Additionally, the stock has exhibited erratic trading patterns, having not traded on 2 out of the last 20 days. While it is currently trading above its 5-day moving average, it remains below its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend.<BR><BR>Despite a notable increase in investor participation, with a delivery volume on December 3 rising by 376.98% against the 5-day average, the overall sentiment appears negative, contributing to the stock's decline. The liquidity of the stock is adequate for trading, but the persistent underperformance compared to the benchmark and sector indicates ongoing challenges for Solara Active Pharma Sciences Ltd.